Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
AstraZeneca said its breast cancer drug received FDA accelerated approval, based on an FDA-authorised blood test detecting emerging ESR1 mutations tied to reduced effectiveness of current treatment. The decision follows Phase III SERENA-6 trial results.
AstraZeneca said its breast cancer drug Etcamah (camizestrant), used with a CDK4/6 inhibitor, received accelerated approval in the US for patients with a common form of advanced breast cancer showing resistance signs.